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A B S T R A C T
There have been substantial improvements made in the tools and techniques used since the advent of
percutaneous coronary intervention. What was primarily developed as a treatment of coronary artery
disease is now used to address a variety of structural heart disease problems. The outcomes have been
remarkably successful with relatively low complication rates that rival the results of open-heart surgery.
This article will review some of the new devices available for management of structural cardiac
conditions including congenital defects and acquired valvular abnormalities. Transcatheter treatment
offers advantages over surgical intervention in recovery time, improved patient satisfaction, lower
procedural risk, and avoidance of cardio-pulmonary bypass especially in high-risk patients. We will
discuss different medical conditions and introduce the devices used to treat these conditions. Each
device or technique has beneﬁts and risks, and familiarity with the devices along with patient selection
will best optimize the outcome.
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.Contents
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Signiﬁcant improvements have been made in the tools and
techniques used since the advent of percutaneous coronary
intervention. What was primarily developed as a treatment of* Corresponding author at: 10833 Le Conte Avenue, Factor Building, Room B-976,
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0914-5087/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightscoronary artery disease has become adapted to address the
problems associated with structural heart disease. The outcomes
have been remarkably successful with relatively low complication
rates that rival the results of open-heart surgery [1]. There has been
a continuous trend to use endovascular techniques for manage-
ment of most cardiac conditions while simultaneously minimizing
open surgical interventions.
This article will review some of the new devices available for
management of a variety of structural cardiac conditions such asreserved.
[(Fig._2)TD$FIG]
Fig. 2. Amplatzer cribriform device.[(Fig._3)TD$FIG]
Fig. 3. Gore-Helex device.
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abnormalities. Transcatheter treatment offers advantages over
surgical intervention in recovery time, improved patient satisfac-
tion, lower procedural risk, and avoidance of cardio-pulmonary
bypass especially in high-risk patients.
Atrial septal defects
An atrial septal defect (ASD) is the second most common
congenital heart defect occurring in 8 of 1000 live births. Small
defects less than 1 cm may be discovered without any clinical
symptoms since they do not produce signiﬁcant shunting of blood
and thus do not require closure. Larger defects with a Qp:Qs ratio
greater than 1:1.4 may produce hemodynamic consequences
consisting of atrial arrhythmias or right heart failure and should
be closed. Only a secundum ASD may be closed by transcatheter
devices rather than open-chest surgery, provided the anatomy is
amenable with sufﬁcient rims to hold a device. The most common
device is the Amplatzer septal occluder (ASO, St. Jude Medical, St.
Paul, MN, USA) (Fig. 1). The device is composed of a self-expanding
double disk with a short connecting waist that acts to center the
device within the defect. The device is made from 0.004 to 0.008-
inch nitinol wire mesh that covers a polyester material to reduce
blood ﬂow through the device. Fibrous tissue ingrowth occurs in a
few months to provide a biologic seal. The size of the device is
selectedbymeasuring thediameterof the septaldefect, usuallywith
an inﬂated sizing balloon. The Amplatzer device is available in sizes
of 4 mm to 38mm in the USA and up to 40mm in the rest of the
world. Depending on the size of the device chosen, the overhang for
the atrial disks ranges from 6 to 8 mm. The device is easy to deploy
except for large ASDs and has proven to be reliablewith a low risk of
complicationsor failureof implantation [2]. It is estimated that there
have been over 200,000 percutaneous ASD implants worldwide. An
ASD may also exhibit multiple fenestrations in the inter-atrial
septum, which are too small to accommodate an ASO waist. These
may require the use of the Amplatzer Multi-Fenestrated Septal
Occluder or cribriformdevice (Fig. 2). Unlike theASO, this device has
matchedatrial disk sizes toensuremaximal coverageof surrounding
fenestrations, and a narrow waist to pass through the smaller
defects. Two or three devices can be implanted close to each other to
cover awider area or an aneurysmal fenestrated septum. Long-term
outcomes and facility of deployment is similar to the ASO.
Complications related to the ASO range from 0.6 to 1%, with the
worst complication, erosion, occurring in approximately 0.1%
[3]. Although rare, allergy to nickel may cause complications
including chest pain due to inﬂammation that requires surgical
extraction of the device in about 0.2% [4].
A second device commonly used to close ASDs is theGore-Helex
septal occluder (Gore & Associates, Inc., Flagstaff, AZ, USA) (Fig. 3).
The device is composed of a nitinol wire on an ePTFE (expanded[(Fig._1)TD$FIG]Fig. 1. Amplatzer septal occluder and delivery cable.polytetraﬂuoroethylene) patch creating a helix with 1.5 turns in
the left atrium and 1.5 turns on the right side. The device is not self-
centering so a device to defect diameter size of 2:1 is required so
that an edge cannot prolapse through the ASD. The Gore-Helex
occluder is a good option for smaller defects less than 13 mm in
diameter. No erosions or allergic reactions to nickel have been
documented with this device. There is a higher likelihood of wire
fracture but this has not translated to an adverse clinical outcome
or displacement. The CardioSeal and STARﬂex devices (NMT
Medical, Inc., Boston, MA, USA) were previously available for ASD
closures. Due to a high frequency of residual shunts, and lower
procedural success rates of 85%, the devices are no longer available
on the market worldwide [5].
Gore & Associates is currently evaluating a new septal occluder
(Fig. 4). This device is composed of a 5-wire support frame covered
with ePTFE. The device is intended to conform better to septal
anatomy while maintaining stronger radial compression and
reduced shunting compared with their previous design. All of the
ASD devices are retrievable before release.
Patent foramen ovale
A patent foramen ovale (PFO) is a congenital inter-atrial
pathway that persists in 20–30% of the population. In utero, the
foramen ovale permits shunting of oxygenated placental blood to[(Fig._4)TD$FIG]Fig. 4. Gore septal occluder (not yet approved).
[(Fig._6)TD$FIG]
Fig. 6. Amplatzer duct occluder.
[(Fig._7)TD$FIG]
Fig. 7. The Nit-Occlud device in deployed conﬁguration.
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and perfuse the critical organs [6]. Placental blood only has an
oxygen saturation of 67% and would not be sufﬁcient to sustain
organogenesis if it lost more oxygen passing through the non-
aerated fetal lung. This mechanism is so important that it is
preserved throughout evolution in all mammals. After birth,
venous return no longer provides oxygenated blood and the
septum primum and septum secundum fuse to become the
foramen ovale. Should fusion not occur, the foramen ovale remains
patent but is typically asymptomatic. In a minority of patients,
symptoms do occur as there is an association of PFO with
cryptogenic stroke, migraines with aura, orthodeoxia platypnea,
decompression illness, high altitude pulmonary edema, and
exacerbation of obstructive sleep apnea [7]. The ASO and Gore-
Helex devices discussed above for closure of an ASD are also used
for PFOs with similar success and low complication rates. These
devices, however, are not approved by the US Food and Drug
Administration (FDA) for treatment of PFOs and their use is
considered off-label in the USA. An Amplatzer device designed
speciﬁcally for PFO anatomy is available in the rest of the world.
Patent ductus arteriosus
The patent ductus arteriosus (PDA) is a second fetal shunt that
carries oxygenated placental blood from the pulmonary artery to
the aorta, bypassing the lungs in utero. A PDA is less likely to be
present in adults since most PDA shunts are diagnosed in
childhood and treated. A delay in diagnosis can have signiﬁcant
hemodynamic implications including pulmonary hypertension
and Eisenmenger’s syndrome with reversal of left to right
shunting. If pulmonary artery pressure is sufﬁciently high, closure
of a large PDA later in life may be contra-indicated since it acts as a
pop-off valve to prevent right heart failure. Other possible sequelae
of a PDA include endocarditis, high output heart failure, and
arrhythmias. Prior to closure of a PDA, a full hemodynamic study
should be performed to judge suitability of closure and to measure
the duct length and diameter by bi-plane angiography during
opaciﬁcation of the duct. A calciﬁed PDA can be difﬁcult to close
surgically as the calciﬁed vessel may fracture causing catastrophic
bleeding. Transcatheter closure can be accomplished using
embolization coils such as Gianturco coils (Fig. 5), the Amplatzer
duct occluder (Fig. 6), or more recently, the Nit-Occlud device
(Fig. 7) (pfm medical ag, Ko¨ln, Germany). To deliver the device to
the appropriate location in the ductus, the operator advances a
wire from the arterial side and enters the PDA through the aorta.
The wire is then snared in the pulmonary artery and externalized
creating a rail. The chosen device is then advanced across the PDA
from the pulmonary artery side over the wire to deploy the
occluder device. Multiple coils are available on the market
including detachable ones that allow the operator to assess
position and stability before releasing the coil from the delivery[(Fig._5)TD$FIG]Fig. 5. Embolization coils (expanded).cable. Two versions of the Amplatzer duct occluder (ADO) exist.
The ADO-I has a conical shape with a retention skirt on the arterial
side to secure the device. It has a relatively simple deployment
technique and high success rate with over 95% of treated patients
achieving ductal closure at 6 months [8]. Sizing selection requires
that the smaller end of the device be at least 2 mm larger than the
narrowest portion of the PDAmeasured by angiography. The ADO-
II device is a compliant dual articulating disc device with a
symmetrical design. It allows the operator to achieve closure from
either the aortic or pulmonary artery side as both sides have a
retention disc. More attention has to be paid to the waist length on
this device compared to the duct to allow the distal disc to expand
appropriately. The Nit-Occlud PDA occlusion device is a relatively
new device with an atraumatic biconical conﬁguration and
variable stiffness. The larger more stiff conical component con-
forms to the aortic side forming a plug with the rest of the coil
winding inside the ductal tunnel. A small coil on the pulmonary
side anchors the device in place.
Ventricular septal defects
A ventricular septal defect (VSD) is an incomplete fusion of the
inter-ventricular wall. It can exist in the muscular ventricular
septum, the membranous portion close to the atrioventricular
node, sub-arterial or supracristal, or as an inlet type VSD [9]. The
most common is the muscular VSD, which, if small, may close
spontaneously in early childhood. Membranous VSDs are more
common in older children and adults since they do not typically
close spontaneously. The defects that may be managed by
transcatheter techniques are the perimembranous and muscular
VSDs. VSDs that occur post-myocardial infarct with rupture of the
ventricular septum are a special category associated with a high
[(Fig._9)TD$FIG]
Fig. 9. Amplatzer muscular VSD post-infarct occluder.
[(Fig._10)TD$FIG]
Fig. 10.Amplatzermembranous VSD occluder. The device is eccentricwith a shorter
disc overhang on the valve side and longer ventricular side. The device is sized
according to the waist (A). The right ventricular disc (B) is symmetric. A marker at
the distal or lower part of image of the left sided disc (C) identiﬁes the orientation
angiographically.
[(Fig._8)TD$FIG]
Fig. 8. Amplatzer muscular VSD occluder.
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patients. VSDs can be associated with signiﬁcant sequelae
including heart failure, pulmonary hypertension, conduction
abnormalities, and valvular dysfunction [10]. Transcatheter clo-
sure of a VSD can be technically challenging but may produce
satisfactory long-term outcomes similar to surgery [11,12].
Options for closure include using the Amplatzer series of VSD
devices and the Nit-Occlud device. The Amplatzer muscular VSD
occluder is a double-disk nitinol wire mesh with polyester patch
design similar to the ASD occluder, except that it is designed to ﬁt
the thicker muscular septum. There is a thinner membranous VSD
device and a post-myocardial infarction device with a longer waist
to accommodate damaged muscular tissue. The muscular occluder
has symmetric right and left ventricular disks 8 mm larger than the
waist. The size of the device is determined by using a sizing balloon
tomeasure thewidth of the VSD (Fig. 8). The post-infarct version of
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Chart 1. Average adjusted 5 year survival using constant hazard ratio. National Institute
domain data).
Source: National Institute of Health. National Cancer Institute. Surveillance Epidemiology amyocardial tissue at the rims (Fig. 9). The membranous VSD
occluder is also a self-expanding, self-centering retrievable
double-disk device with a shorter waist. The device is eccentric
with a left-side aortic overhang of 0.5 mm and a left side
ventricular overhang of 5.5 mm. The ventricular end has a
radio-opaque marker to help orient the longer component of the
disk towards the ventricular apex. This allows the device to be
implanted without impinging on the left heart valves (Fig. 10). To
deploy the device, the ﬂat part of the pusher catheter is aligned
with the ﬂat part of the delivery catheter end-screw. A plastic vice
is attached to the end of the delivery catheter to maintain the
orientation of the device before delivery. Care must be taken when
implanting a device across a perimembranous VSD to not cause
disruption of a nearby valve or atrioventricular block. A version of
the Nit-Occlud device is available for perimembranous VSD
closure. This device contains polyester ﬁbers to improve closure.
The device is well suited for aneurysmal perimembranous VSDs,
and there are no reports of permanent atrioventricular-block
[13]. To size the Nit-Occlud, a coil with a distal diameter at least
twice theminimal diameter of the VSD on the right ventricular side
and 1 to 2 mm greater than the diameter of the VSD at the left
ventricular side should be selected.
Aortic stenosis
Transcatheter aortic valve replacement (TAVR) is rapidly
gaining in popularity. Degenerative aortic stenosis is a progressive
disease with high-mortality (Chart 1). Repair of the condition
either by surgical aortic valve replacement (SAVR) or TAVR
changes the natural course substantially with 5 implants needed
to prevent 1 death in a high-risk population [14]. TAVR hasis: 5 Year Surival Rate %
Prostate CA Ovarian CA Severe Inoperable AS
of Health 2010. CA: Metastatic Cancer Incidence. No permission necessary (public
nd End Results. Cancer Stat Fact Sheets. 2010. Edwards Lifesciences LLC – Data on ﬁle.
[(Fig._11)TD$FIG]
Fig. 11. Edwards Sapien valve.
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who do not qualify for SAVR andwill likely becomemore prevalent
as the indications for the procedure expand. Currently, there are
4 series of devices available commercially or in active trials. The
Edwards Sapien valve (Edwards Lifesciences, Irvine, CA, USA) was
studied in the PARTNER trial. This randomized trial demonstrated
signiﬁcant improvement in New York Heart Association (NYHA)
scores and 2-year survival (70%) compared to medical therapy
(50%) in non-surgical patients (cohort B). In patients who were at
high-risk but were acceptable surgical candidates, there were
equivalent long-term outcomes to open surgical intervention at
1 year (cohort A). The original Sapien valve was composed of three
leaﬂets made from bovine pericardial tissue sutured together to a
polyethylene terephthalate (PET) skirt on a balloon expandable
stainless steel stent frame (Fig. 11). It was available in one of
2 diameter sizes: 23 mm or 26 mm. The valve was crimped on a
balloon delivery catheter and advanced retrograde through the
femoral artery (Fig. 12). Alternatively, the valve could be delivered[(Fig._12)TD$FIG]Fig. 12. Edwards Sapien valve crimped on the delivery catheter on left and post-
balloon deployment with rapid pacing on the right.[(Fig._13)TD$FIG]
Fig. 13. Edwards Sapien XT valve.via a trans-apical access through a mini-thoracotomy in the lateral
chest or through the distal ascending aorta via a midline mini-
thoracotomy.
The second generation Edwards valve, the Sapien XT, is a bovine
pericardial tissue valve as well, but is sutured on a cobalt
chromium stent scaffold (Fig. 13). This stent construction allows
the valve to be crimped to a lower proﬁle while maintaining
structural and radial support once expanded. The NovaFlex+
delivery catheter (Edwards Lifesciences) is stretchable, which
allows for a lower vascular access proﬁle. To diminish the
arteriotomy size, the valve is not crimped on the balloon directly
during preparation, but is crimped proximal to the balloon. Once
the delivery catheter is in the ascending aorta, the balloon is pulled
into the valve and is then advanced to the correct position. In
addition, the Sapien XT is available in three diameter sizes: 23 mm,
26 mm, and 29 mm accommodating aortic annulus areas greater
than 490 mm2. These modiﬁcations allowed a reduction in the
delivery sheath sizes to 16, 18, and 20Fr requiring iliac artery
diameters of 6, 6.5, and 7 mm respectively. This resulted in
lowered vascular complication rates compared to the ﬁrst-
generation valves. The ﬁrst-generation Sapien valve required a
24Fr delivery sheath and was associated with a 15.5% incidence of
vascular complications whereas the new generation Sapien valves
have a 9.6% incidence of vascular complications. The incidence of
conduction injury remained low at 6% [14].
The newest generation of transcatheter valves from Edwards is
the Sapien 3 (Fig. 14). This valve is being evaluated in clinical trials
in the USA currently, but is in use elsewhere. It is also a bovine
pericardial leaﬂet valve mounted on a modiﬁed lower proﬁle
cobalt chromium stent frame. An outer skirt helps reduce para-
valvular leaks. The redesigned Edwards Commander delivery
catheter provides additional dual articulation to help better
position the valve coaxially in the outﬂow tract. Improvements
in the design of the catheter and sheath have resulted in a delivery
proﬁle of 14 French for the 23 and 26 mm valves, and 16 French for
the 29 mm valves. These require vessel sizes of 5.5 mm and 6 mm,
respectively.
Medtronic (Minneapolis, MN, USA) acquired the Corevalve in
2009. The valve gained FDA approval in 2014 for patients with
severe symptomatic aortic stenosis who are at high risk for surgical
intervention. The SurTAVI trial demonstrated the efﬁcacy of the
Corevalve compared to surgical intervention with improved one-
year survival (86%) compared to SAVR (81%). The stroke rates were
equivalent at 5.8% and 7% respectively (p = 0.6). The risk of needing
a permanent pacemaker was signiﬁcantly higher, however, at 25–
30% compared to the Sapien series of 5%. The Corevalve is made
from porcine pericardium on a self-expanding nitinol frame
(Fig. 15). The thinner tissue thickness of porcine pericardium as
well as the self-expanding design allowed for a smaller delivery
[(Fig._14)TD$FIG]
Fig. 14. Edwards Sapien 3 valve.
[(Fig._17)TD$FIG]
Fig. 17. The Direct Flow valve made of treated bovine pericardium and a non-
metallic inﬂatable cuff.
[(Fig._15)TD$FIG]
Fig. 15. Medtronic Corevalve and delivery sheath.
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sizes ranging from 23 to 31 mm in diameter which is useful in
patients with a larger aortic annulus. The higher incidence of
conduction block was due to the longer stent design (55 mm)
reaching further down the left ventricular outﬂow tract and the
self-expanding nature of the valve which exerts pressure on the
conducting tissue within the septal wall. Careful valve positioning
and better deployment techniques, such as using a smaller pre-
dilation balloon <23 mm, have resulted in a lower need for
permanent pacemaker implantation of 15% [15]. Additionally, the
persistent radial pressure of the valve scaffold on the aortic wall
decreases para-valvular leaks over time. The Corevalve does not
require rapid pacing to be deployed, but moderate pacing of 90–
120 bpm may better stabilize the valve in patients with severe
regurgitation or ectopy.
St. Jude Medical has been evaluating a trans-catheter valve, the
Portico valve, in the TF CE Trial. This valve consists of bovine
pericardial tissue on a self-expanding nitinol stent structure. The
stent is shorter than the Corevalve reducing the risk for conduction
injury, and like the Corevalve, the self-expanding design obviates
the need for rapid pacing during deployment. The Portico valve is
deployed through an 18 French delivery sheath. Currently, only a
23 mm valve is available but a 25 mm valve is being developed
(Fig. 16).
The Direct Flow valve (Direct Flow Medical, Santa Rosa, CA,
USA) is a non-metallic valve made of bovine pericardium, and a
conformable expandable cuff (Fig. 17). Once the valve is in position
across the annulus, the cuff is inﬂatedwith a liquid plastic polymer
that hardens keeping the cuff in place. This creates an atraumatic
seal. The system is introduced using an 18Fr sheath and is both
repositionable and retrievable. Smaller trials were conducted in
the USA and the larger SALUS trial was initiated in May 2014.
Currently in the USA, only patients with severe symptomatic
degenerative aortic stenosis qualify for TAVR. Interventions for
aortic regurgitation or bicuspid valves have been performed but
have not gained FDAapproval in theUSA. Valve-in-valve procedures
are also off-label but have been performed in cases where a
previously implantedbio-prosthetic valve has degenerated in a high[(Fig._16)TD$FIG]Fig. 16. St. Jude Portico valve.surgical riskpatient. Trans-catheter valveshavebeenused to correct
valvular dysfunction in themitral, pulmonic and tricuspidpositions.
Mitral stenosis
Mitral stenosis has decreased in incidence in developed
countries but continues to be prevalent in much of the world.
The primary cause is rheumatic mitral disease. Other less common
causes include infective endocarditis, severe mitral calciﬁcation,
lupus erythematosis, inﬁltrative disease, and advanced carcinoid.
As the mitral valve area decreases, ﬁlling of the left ventricle is
impaired and, with higher heart rates, the diastolic ﬁlling time is
reduced. This produces increased left atrial pressure and pulmo-
nary congestion [16]. The left atrium becomes dilated, which
predisposes to atrial ﬁbrillation and thromboemboli. Until the
early 1980s, the only option was surgical valve replacement as the
scarred rheumatic mitral valves are not typically amenable to
repair. Percutaneous balloon commissurotomy can be performed
using a double balloon technique, which is rarely used, or the
single Inoue balloon. The Inoue balloon has made mitral
commissurotomy a more stable and straightforward minimally
invasive procedure (Fig. 18). The balloon is made of a polyester
micromesh between two latex layers. The balloon is self-centering
due to the creation of a waist in the middle. It is available in three
sizes that cover a range of 24–30 mm in diameter. Careful review of
the mitral valve anatomy is required to assess suitability; heavily
calciﬁed commissures are unlikely to yield and may rupture. A
calibrated syringe helps ﬁll the balloon to the desired diameter in a
progressive fashion. A balloon stretching tube is used with the
inner tube to stretch the Inoue balloon as it is introduced into the
body and across the septum to slenderize it, giving it a lower
proﬁle. A dilator and guide wire are included to dilate both the
venous entry point and the septum, and then maintain access
across the atrial septum. A curved stylet directs the balloon at the[(Fig._18)TD$FIG]Fig. 18. Inoue balloon and hub.
[(Fig._19)TD$FIG]
Fig. 19. Transesophageal echocardiography image of the Inoue balloon expanded
across a stenotic mitral valve.
[(Fig._21)TD$FIG]
Fig. 21. The Carillon mitral contour system.
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When performed by experienced operators, the procedure has a
high technical success rate of 99%. Complications include a 1.5%
risk for embolic events, 23% risk for increase inmitral regurgitation
(MR), 4% risk for MR requiring repair, and a 1% risk of death.
Mitral regurgitation
MR is more common than mitral stenosis and is categorized
depending on whether there is a structural abnormality of the
valve leaﬂets or chordae or if the regurgitation is due to valve
dysfunction created by LV dilatation. The most common cause of
structural MR is valve prolapse due to myxomatous degeneration
and chordal stretching. Dilated cardiomyopathy of any etiology is
the most common cause of functional MR [17]. There are several
devices that have been developed for percutaneous repair of mitral
regurgitation including the MitraClip (Abbott Laboratories, Abbott
Park, IL, USA), Carillon (Cardiac Dimensions Inc., Kirkland, WA,
USA), Cardioband (Valtech, Boston, MA, USA), MONARC (Edwards
Lifesciences, Irvine, CA, USA), Mitralign (Mitralign, Tewksbury, MA,
USA), and trans-catheter mitral valve replacement.
The MitraClip was developed to percutaneously recreate the
Alﬁeri stitch described in 1991 to treat mitral regurgitation by
creating a double oriﬁce for themitral valve by clipping themiddle
edges of the anterior and posterior mitral leaﬂets together. The
Everest II trial demonstrated efﬁcacy of the device in high-risk
surgical patients and MitraClip has gained widespread use outside
the USA with expanding indications (Fig. 20). The device is[(Fig._20)TD$FIG]Fig. 20. The MitraClip deployment systecomposed of a steerable 24Fr guide-catheter that is placed from
the inferior vena cava (IVC) across the atrial septum. The MitraClip
device is made of cobalt chromium with a polyester cover. The
delivery system controls two separate MitraClip arms to stabilize
then grasp the mitral leaﬂets. Once an appropriate position is
attained, the clip is closed and the leaﬂets are secured. The
EVEREST II trial demonstrated improved safety in the transcatheter
treated group primarily due to lower bleeding rates comparedwith
surgery. High-risk patients (Society of Thoracic Surgeons’ risk
model (STS) score > 12) with functional MR demonstrated
procedural success of 76% that was sustained at 12 months. The
need for mitral valve surgery at one year was low at under 6% with
maintenance of NYHA functional class I/II for 75% of surviving
patients [18].
A second approach to treating functional MR is to use the
proximity of the great cardiac vein to the mitral annulus. A device
is delivered from the right internal jugular vein through the
coronary sinus just proximal to the takeoff of the anterior
interventricular vein. A distal anchor is secured and then the
atrial tissue is plicated by pulling tension on the device, which
simultaneously pulls on the tissue around the mitral annulus. The
plication of tissue approximates the anterior and posterior mitral
leaﬂets to decrease the regurgitant ﬂow. There is a risk of
circumﬂex coronary artery compression as branches of this vessel
may pass under the great cardiac vein in 27% of hearts. As the
device is delivered via the right heart and through the coronary
sinus, the procedural risk is low.
The Carillon mitral contour system is a coronary sinus implant
that consists of a proximal and distal anchor connected by a nitinol
shaping ribbon (Fig. 21). The distal anchor is delivered in the great
cardiac vein and after tension is applied, the proximal anchor is
delivered near the ostium of the coronary sinus. The immediate
effect on MR is assessed by transesophageal echocardiography
(TEE) and coronary compression is evaluated before release. The
tension can then be adjusted or the device retrieved as necessary.
The Mitralign is a direct mitral annuloplasty device. It is
implanted directly on the mitral annulus to avoid the risk of
coronary compression seen with coronary sinus approaches. This
device delivers two pledgette sutures near the P1 and P3 leaﬂets.
The sutures are then plicated, tightening the posterior leaﬂet andm on left, and the clip on the right.
[(Fig._23)TD$FIG]
Fig. 23. The Amplatzer vascular plug.
[(Fig._24)TD$FIG]
Fig. 24. The Amplatzer vascular plug II.
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Systems device (Guided Delivery Systems, Santa Clara, CA, USA)
introduces a catheter into the left ventricle retrograde from the
aorta. The catheter is then used to deliver several anchors on the
ventricular aspect of the posterior leaﬂet. The anchors are
‘‘cinched’’ together reducing the valve annular diameter. The
Cardioband device attempts to reproduce the effects of a surgical
annuloplasty in that it delivers a ﬂexible ring onto the atrial side of
the valve to ‘‘cinch’’ the posterior leaﬂet closer. There have been
about 25 cases performed with effective reduction in the degree of
mitral regurgitation.
Due to the more complex anatomy of the mitral valve and
surrounding structures, a trans-catheter solution for mitral valve
replacement is still not mature at this time. Several valves are
being developed to overcome challenges such as increased wall
stress, pressure, and asymmetric chamber geometry. If the patient
already has a surgically implanted bio-prosthetic valve, however,
the option exists for implanting a currently available device such as
the Edwards Sapien valve as a ‘‘valve-in-valve’’ procedure. The
previously implanted prosthesis acts as an anchoring ring for the
valve stent with good procedural success rates and improvement
in outcomes and function [19].
Pulmonic valve stenosis and regurgitation
Improvement in the management of congenital heart disease
patients at an early stage has increased survival which reveals
subsequent problems as these patients grow older. Pulmonic valve
stenosis may be congenital, acquired, or associated with more
complex congenital heart diseases. Balloon valvuloplasty can be
used in isolated stenosis with good long-termoutcomes [20]. Valve
regurgitation often occurs in the same population, especially after
prior congenital repair such as the Ross procedure or tetralogy of
Fallot repair. Trans-catheter valves are increasingly used in these
cases or where the valve or conduit has degenerated to produce
severe pulmonic insufﬁciency.
The Melody valve (Medtronic) is commercially available with
indications for pulmonic regurgitation or stenosis and a dysfunc-
tional right ventricle with a conduit size greater than 16 mm. It is a
bovine jugular valve on a platinum-iridium stent crimped on a
22Fr Ensemble catheter delivery system (Fig. 22). The delivery
catheter is a balloon-in-balloon systemwith outer diameters of 18,
20, and 22 mm introduced via the femoral vein. Alternatively,
Edwards Lifesciences is investigating the Sapien pulmonic heart
valve. It is a bovine pericardial tissue valve on a stainless steel
frame similar to the Edwards aortic Sapien valve. In positioning
these valves, computed tomography or magnetic resonance
imaging overlay and bi-plane ﬂuoroscopy can be useful. Many
of these patients have complex anatomy or unusual cardiac
orientations so precise positioning is important. This avoids
placing the valves in dilated or deformed conduits, or possible
compression of coronary arteries or impinging other structures.
[(Fig._22)TD$FIG]Fig. 22. The Medtronic Melody valve (expanded).Paravalvular leaks
Paravalvular leaks occur when the annulus of an implanted
valve does not fully oppose the annulus around it, whichmay occur
due to disruption of ring sutures or annulus dilation. The leaksmay
be hemodynamically signiﬁcant or can be associated with
signiﬁcant hemolysis. Moderate regurgitation results in worse
patient outcomes [21]. No device is currently approved in the USA
and catheter-based interventions are performed off-label. Vascular
plugs are most often used for closure. The most common of these
are the Amplatzer family of plugs (St. Jude Medical). These plugs
are made of a nitinol mesh delivered by a cable through a catheter
system. The Amplatzer Vascular Plug (AVP) is a cylinder shaped
self-expanding plug available in diameters from 4 to 16 mm
(Fig. 23). The AVP-II is multi-segmented with discs on both ends.
These stabilize the device in larger leaks and limit ﬂow through the
defect reducing time to occlusion (Fig. 24). It is available in sizes
from 3 to 22 mm. The AVP-4 is a low-proﬁle bi-lobed device on a
ﬂexible delivery wire that allows for easier maneuverability
(Fig. 25). This device can be delivered through a 0.035 inch ID (4Fr)
catheter and is available in sizes from 4 to 8 mm. It is also possible[(Fig._25)TD$FIG]
Fig. 25. The Amplatzer vascular plug 4.
[(Fig._27)TD$FIG]
Fig. 27. The Atrium Advanta covered stent.
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paravalvular leaks. Careful assessment of the defect orientation
and size is necessary before and during the procedure. TEEwith 3D
imaging has made these complex procedures much easier to
perform since the operator can visualize the orientation of the leak
relative to the catheter. For crescentic defects, more than one
device may be needed to cover a large area [22]. The AVP-III device
is oval and is beneﬁcial in these types of paravalvular leaks, but it is
only available outside the USA.
Coarctation of the aorta
Coarctation of the aorta is a congenital condition producing a
discrete narrowing of the aorta typically at the ligamentum
arteriosum just distal to the left subclavian artery. This condition is
associatedwith bicuspid aortic valves in about 50% and aortopathy
(where the aorta dilates in a fusiform aneurysm) in 56–88% of
those aged 30 and 80 years respectively [23].
Early repair of the stenosis with an expandable stent improves
long-term outcomes [24]. The procedure has potential risks as
expanding a stent may tear the tunica intima. Covered stents are
preferable and surgical backup should be available when
performing this procedure in case of wall injury and aortic
rupture. The aorta exerts recoil force after balloon expansion so a
device with high radial strength is necessary. The procedure is
usually performed on children and young adults under general
anesthesia. A 14–16Fr access is obtained in the femoral artery and a
long sheath is introduced to the aortic arch past the narrowing.
Stents are mounted on a balloon-in-balloon system (BIB, NuMed,
Hopkinton, KY, USA and pfm medical) that allows for a more
precise and controlled stent expansion in the coarctation (Fig. 26).
The outer balloons range in size from 8 to 24 mm. Once the stent is
in position, the sheath is withdrawn to unsheath the stent before
deployment. Many stents are available for younger children, but as
patients grow, the stents will need to be expanded to a larger
diameter of around 20–30 mm [25]. The most commonly used
stents are the Palmaz XL stent (Johnson& Johnson, NewBrunswick,
NJ, USA), the Palmaz Genesis (Johnson & Johnson), Cheatham-
Platinum (CP) stent (NuMed), the IntraStent (Covidien, ev3,
Plymouth, MN, USA), and the Atrium Advanta stent (Atrium
Medical, Hudson, NH, USA).
The Palmaz XL is a laser-cut closed-cell stainless steel stentwith
high radial strength. It is available in lengths of 31, 40, and 50 mm
and must be expanded to a minimum diameter of 10 mm limiting[(Fig._26)TD$FIG]Fig. 26. Balloon-in-balloon (BIB).its use in smaller children. The Palmaz Genesis stent is similarly a
stainless steel closed-cell stent with curved segments allowing for
improved conformability. This stent is available in lengths of 19,
25, 29, 39, and 59 mm. As this stent is limited at full expansion to
19 mm, it is not optimal for patients who are expected to grow to a
normal sized aorta. The CP stent is a 0.013-inch platinum-iridium
frame welded at each joint and over brazed with gold. The stent
may be expanded from 12.0 to 24.0 mm. A covered version of the
stent has an expandable sleeve of ePTFE.
The IntraStent LD is an open-cell stainless steel stent with less
radial strength but greater ﬂexibility and conformability. The
IntraStent LD may be dilated up to 26 mm, and is delivered via a
smaller 8 French sheath.
The Atrium Advanta series is an encapsulated covered stent
where the ePTFE is on both the inside and outside of the stent. It
may be dilated up to 22 mm and is available with 12-, 14-, and 16-
mm balloons (Fig. 27).
Peripheral arteriovenous ﬁstula
Arteriovenous (AV) ﬁstulae are abnormal communications
between arteries and veins. They occur congenitally as a
consequence of a pathologic process, such as hereditary hemor-
rhagic telangiectasia (HHT) due to lack of inhibition of endothelial
growth factors, injury, or after surgery such as the Fontan repair.
Hemodynamic studies may show persistent elevation of right
heart pressures, or reduced peripheral vascular resistance. These
AV ﬁstulae tend to be fragile with risk of rupture. Pulmonary AV
ﬁstulae bypass the lungs delivering de-oxygenated blood to the left
circulation [26]. If possible, decompression of the pressure causing
the AV ﬁstula will resolve peripheral AV ﬁstula but, along with
surgery, percutaneous options are available. Coil embolization is
usually successful and relatively safe. For pulmonary AV ﬁstula the
operator introduces a Berman catheter; and angiograms of the
pulmonary artery and veins in the Levo-phase are obtained. Once
the AV ﬁstula is identiﬁed, a catheter is advanced over a wire to the
vessel and the AV ﬁstula is engaged. Coils of the appropriate
diameter and length are then introduced to block the abnormal
ﬂow. AV ﬁstulae outside of the pulmonary circulation may be
closed inmuch the same fashion. For peripheral AVﬁstulae, alcohol
sclerotherapy has been used, but there is an increased risk of
peripheral nerve injury, especially in ﬁstulae with high ﬂow.
Coronary artery ﬁstula
Coronary artery ﬁstulae bypass the myocardial capillary bed
and attach to the pulmonary or venous circulation. If the coronary
artery communicates with a cardiac chamber, it is called a
coronary-cameral ﬁstula. Sizable ﬁstulae of greater than three
times the size of a coronary may cause angina due to a steal
syndrome and increased chamber pressures. Deploying emboliza-
tion coils from the venous side has the advantage of reducing the
likelihood of occluding the coronary circulation. It may be
challenging to enter the AV ﬁstula from the venous side, especially
if the connection is through a chamber. A coronary wire can be
advanced across the AV ﬁstula and snared from the venous side. It
is then carefully externalized through a guide catheter taking care
[(Fig._30)TD$FIG]
Fig. 30. The Amplatzer cardiac plug positioning in the left atrial appendage.
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catheter is then advanced over the wire into the AV ﬁstula to
deliver the appropriate coils. In larger ﬁstulae, vascular plug
devices may be used.
Left atrial appendage occlusion
Atrial ﬁbrillation affects more than 10% of people over the age
of 80 years and increases in prevalence with age. The lifetime risk
of having atrial ﬁbrillation is 25% [27]. Atrial ﬁbrillation increases
the risk for developing cerebral and non-cerebral embolic events.
The CHA2DS2-VASc score helps predict the risk of developing
emboli for patients with atrial ﬁbrillation who do not have
associated mitral stenosis. Approximately 90% of emboli develop
in the left atrial appendage due to stagnation of blood ﬂow during
atrial ﬁbrillation [28]. Trans-catheter devices that occlude the left
atrial appendage are attractive as an option to reduce the risk of
emboli especially in patients intolerant of anticoagulation
therapy or at an increased risk of bleeding with a high HAS-BLED
score.
The Watchman device (Atritech, Inc., Minneapolis, MN, USA) is
a self-expanding nitinol framewith ﬁxation barbs and a permeable
polyester fabric that covers the atrial side of the device (Fig. 28).
The device is available in diameters from 21 to 33 mm. Left atrial
appendage anatomy varies among patients so careful assessment
by imaging and angiography should guide selection of the device
size. After a trans-septal puncture, the device is delivered via a 12Fr
catheter into the left atrial appendage. Trans-esophageal imaging
is used during the procedure to ensure adequate ﬁxation while
covering the entire opening of the appendage.
The Amplatzer cardiac plug (St. Jude Medical) is also a left atrial
appendage-occluding device that is made from a ﬂexible nitinol
wire mesh. The device is softer and more ﬂexible than the ASD
occluder series. The device has a self-orienting disk on an
articulating neck (Fig. 29). This allows the distal part of the device
[(Fig._28)TD$FIG]
Fig. 28. The Watchman left atrial appendage occluder.
[(Fig._29)TD$FIG]
Fig. 29. The Amplatzer cardiac plug.to occupy the left atrial appendage lobe for anchoring. The
proximal articulating disk then achieves full coverage of the
appendage opening and ismetaphorically termed the ‘‘garbage can
cover’’ to the LAA (Fig. 30). Device sizing depends on the distal
inner-wall lobe and ranges from 16 to 30 mm. The outer disk is
4 mm larger for lobes smaller than 24 mm and 6 mm for larger
appendages. The device is available internationally but not yet
approved in the USA.
A third device in use is the Lariat suture delivery system
(SentreHeart, Redwood, CA, USA). The device delivers a 40 mm
pre-tied suture loop around the appendage to occlude it from the
outside. A wire and catheter is advanced up the IVC and across
the septum into the left atrial appendage. The wire contains a
magnet at the tip. A dry pericardial tap is done under the left
para-xiphoid area and a second wire with a tip-magnet is
advanced along the lateral border of the heart until it meets the
ﬁrst magnet. The suture loop is then advanced along the
pericardial wire and manipulated over the appendage until it
surrounds the opening of the left atrial appendage. To help in
positioning, a balloon is inﬂated in the appendage. The loop is
then tightened to attain adequate appendage occlusion. Com-
plications of this procedure include a moderate amount of pain
and residual pericarditis which may be modulated by pre-
treatment with colchicine.
Stem cell therapy
Stem cell therapy for a multitude of medical problems has
gained widespread interest since 2000. The extension of stem cell
therapy for cardiac conditions is takingmany approaches. Positive
results have been obtained in animal studies, and early human
trials suggestmild beneﬁts. The greatest promise of the therapy is
in the treatment of heart failure after infarct for recovery of
cardiac function. The concept of stem cell therapy is to use multi-
potent progenitor cells to take over diseased or infarcted cardiac
muscle tissue. These cells are active during neonatal and early
infant life but are reduced substantially in the adult and enter a
quiescent stage. Work is being done to understand the signaling
mechanisms to both reactivate and attract the multi-potent cells
to the site of injury [29]. The ideal cell type for this therapy is being
evaluated. Multiple cell lines are being tested, includingmyoblast
cells from skeletal cells, CD35 cells from bone marrow or from
apheresis. Other agents used include hormones and signaling
molecules to attract and activate progenitor cells. Another
variable is the delivery technique that will demonstrate the best
clinical efﬁcacy.
To target the cells to the injured myocardium and encourage
engraftment, several techniques are being studied. One tech-
nique involves infusing the cells after they are isolated and
proliferate in vitro, via an intra-coronary catheter directly into a
[(Fig._31)TD$FIG]
Fig. 31. Skeletal myoblasts in cell culture.
[(Fig._33)TD$FIG]
Fig. 33. NOGA mapping of the left ventricle. Color represents regional voltage map
from blue (highest) to red (lowest) voltage potential.
J.M. Tobis, I. Abudayyeh / Journal of Cardiology 65 (2015) 5–16 15coronary artery supplying the injured myocardium post-infarct.
Another approach is to infuse signaling chemicals intravenously
to activate a paracrine mechanism and stimulate resident
cardiac stem cells [30]. These techniques depend on margination
and adherence of the biologic agent to the site of prior injury
(Fig. 31).
A more direct technique involves injecting the harvested cells
into the targeted myocardium by use of a needle-tipped catheter
and a mapping system. Several needle catheters have been
developed including the BioCardia (San Carlos, CA, USA), and
Myostar (Biosense Webster Inc., Diamond Bar, CA, USA). These
catheters share similar characteristics in that they are de-
ﬂectable and deliver the cells via a needle directly into the
muscle (Fig. 32). To target areas of injury, the NOGA mapping
system (Biosense Webster Inc.) is used to create an electric map
with the assumption that low residual activity corresponds to an
area of injured myocytes (Fig. 33). It is important to recognize
that the choice of the agent and delivery method are dependent
variables inﬂuencing the efﬁcacy of each other and affecting
clinical success. At this time, there is no consensus as to which
cells or method of delivery is preferable for cardiac applications,
but there is a wealth of preclinical and early clinical data
showing safety, feasibility, and mild efﬁcacy of adult cell-based
therapy. It is hoped that this new ﬁeld will have future beneﬁt
for the treatment of conditions such as severe angina or heart
failure.[(Fig._32)TD$FIG]
Fig. 32. Deﬂectable intra-cardiac biologic agent delivery catheter.References
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